We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+75.12%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$96.8M
AUM Growth
+$25.1M
Cap. Flow
-$7.48M
Cap. Flow %
-7.73%
Top 10 Hldgs %
75.97%
Holding
36
New
8
Increased
5
Reduced
13
Closed
8

Top Buys

Rank Stock Value
1
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$3.14M
2
CMPX icon
Compass Therapeutics
CMPX
+$2.65M
3
OCUL icon
Ocular Therapeutix
OCUL
+$1.8M
4
KRYS icon
Krystal Biotech
KRYS
+$1.58M
5
DRUG
Bright Minds Biosciences
DRUG
+$1.41M

Top Sells

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$5.31M
2
TRVI icon
Trevi Therapeutics
TRVI
+$2.7M
3
CDTX
Cidara Therapeutics
CDTX
+$2.43M
4
ASND icon
Ascendis Pharma A/S
ASND
+$2.38M
5
BBOT
BridgeBio Oncology
BBOT
+$1.99M

Sector Composition

Rank Sector Weight
1 Healthcare 99.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RVMD icon
26
Revolution Medicines
RVMD
$44B
$393K 0.41%
8,411
-47,282
-85% -$1.85M
UNCY icon
27
Unicycive Therapeutics
UNCY
$139M
$262K 0.27%
59,985
-2,914
-5% -$12.7K
NUVB.WS
28
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$18.4K 0.02%
90,832
– –
AKRO
29
DELISTED
Akero Therapeutics
AKRO
– –
-19,772
Closed -$1.06M
LQDA icon
30
Liquidia Corp
LQDA
$8.02B
– –
-75,876
Closed -$945K
RARE icon
31
Ultragenyx Pharmaceutical
RARE
$2.55B
– –
-23,814
Closed -$866K
SLNO
32
DELISTED
Soleno Therapeutics
SLNO
– –
-63,436
Closed -$5.31M
TRVI icon
33
Trevi Therapeutics
TRVI
$2.63B
– –
-493,735
Closed -$2.7M
BBOT
34
BridgeBio Oncology
BBOT
$747M
– –
-187,257
Closed -$1.99M
RAPP
35
Rapport Therapeutics
RAPP
$2.18B
– –
-20,000
Closed -$227K
ARTV
36
Artiva Biotherapeutics
ARTV
$551M
– –
-45,456
Closed -$68.6K
1
2

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
POIA
Pin Oak Investment Advisors Houston, Texas $141M AUM 20.83% 1-Year Est. Return
TM
TFJ Management Somerville, Massachusetts $141M AUM 9.28% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM

Acuta Capital Partners's Q3 2025 Portfolio in Review

As of Q3 2025, Acuta Capital Partners held 36 positions worth $96.8M, up 35% from $71.6M the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Acuta Capital Partners withdrew a net $7.48M in Q3 2025, closing 8 positions and reducing 13 holdings. Its most notable exit was Soleno Therapeutics, an estimated $5.31M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

Against the trend, Acuta Capital Partners opened a new position in Amylyx Pharmaceuticals worth $4.53M.

  • Acuta Capital Partners's largest Q3 2025 buy was Amylyx Pharmaceuticals: 333,258 shares worth $4.53M.
  • Acuta Capital Partners added most to Ocular Therapeutix in Q3 2025, an estimated $1.8M increase.
  • Acuta Capital Partners's biggest Q3 2025 reduction was Cidara Therapeutics, cutting an estimated $2.43M.
  • Acuta Capital Partners fully exited Soleno Therapeutics in Q3 2025, selling an estimated $5.31M.
  • Acuta Capital Partners's ten largest holdings make up 76% of its $96.8M portfolio in Q3 2025.
  • Acuta Capital Partners opened 8 new positions and closed 8 in Q3 2025.
  • Acuta Capital Partners's portfolio value rose 35% quarter-over-quarter to $96.8M.

Based on Acuta Capital Partners's 13F filing for Q3 2025, filed 14 Nov 2025.